RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (GTHX) (Nasdaq: GTHX), a commercial-stage oncology company, and Deimos Biosciences, a portfolio ...
- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments- Genor to lead clinical development, regulatory submissions and commercialization of ...
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug ...
- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments - Genor to lead clinical development, regulatory submissions and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback